UNC Catalyst

@UNC_Catalyst

UNC Catalyst for Rare Diseases - Rapid discovery and development of affordable therapy for rare diseases through innovation and collaboration

Vrijeme pridruživanja: prosinac 2016.

Tweetovi

Blokirali ste korisnika/cu @UNC_Catalyst

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @UNC_Catalyst

  1. proslijedio/la je Tweet
    prije 5 sati

    At the with Paul Workman, David Drewry, and Opher Gileadi to kick off the next phase of our chordoma drug discovery project with . This productive team is tackling a tough "undruggable" target. – mjesto: Institute Of Cancer Research

    Poništi
  2. proslijedio/la je Tweet
    Poništi
  3. proslijedio/la je Tweet
    24. sij

    We are proud to have as a partner in our mission to cultivate awareness and education around Rare Diseases like Cystic Fibrosis.

    Poništi
  4. proslijedio/la je Tweet
    30. sij

    New! Share the official social media visuals for the 2020 campaign now available to download via The visuals are also available in editable files to be translated.

    Poništi
  5. proslijedio/la je Tweet
    30. sij

    Did you know? is an international campaign created with 60 national alliances of rare disease patient organisations from around the world!

    Poništi
  6. proslijedio/la je Tweet
    22. sij

    Very excited that I’m part of the campaign - a very exciting initiative. Watch this space 🦓

    Poništi
  7. proslijedio/la je Tweet

    Have you already checked ? Learn about , their and at http://5.102.147.165/diseases

    Poništi
  8. proslijedio/la je Tweet
    19. sij

    There are currently 7,000 rare diseases affecting 25-30 million Americans today. Join us for our Rare Disease Day 2020 Symposium to raise awareness amongst the general public and decision-makers about rare diseases

    Poništi
  9. proslijedio/la je Tweet
    13. sij

    The Chordoma Foundation Patient Navigation Service is a free & confidential resource that serves the worldwide community by providing personalized info & support to anyone affected by chordoma at any stage of their journey. Need help?

    Poništi
  10. 15. sij

    Excited to see this progress in rare disease research.

    Poništi
  11. proslijedio/la je Tweet
    9. sij

    Locus Biosciences initiates world’s first controlled clinical trial for a CRISPR enhanced bacteriophage therapy:

    Poništi
  12. proslijedio/la je Tweet
    Poništi
  13. proslijedio/la je Tweet
    7. sij

    Out now! Download the official poster for 2020 now available via . Share it today to show your support for the rare disease community!

    Poništi
  14. 6. sij

    Another great example of research into a rare disease that sheds light on more prevalent diseases. In this case understanding tuberous sclerosis can shed light on pathways involved in autism.

    Poništi
  15. proslijedio/la je Tweet
    3. sij

    First post of 2020! A newly-proposed treatment strategy might be effective against several forms of spinocerebellar and other CAG repeat-associated disorders.

    Poništi
  16. 2. sij

    Happy new year! We're so excited to see all the progress 2020 has in store for rare disease treatments!

    Poništi
  17. 21. stu 2019.

    Thanks for visiting our labs and discussing more about Malan Syndrome and how the Catalyst can help shed light on this disease!

    Poništi
  18. 27. velj 2019.

    Excited to meet UNC researchers working on Rare Diseases. Thanks for coming out to support and meet the members of the UNC Catalyst for Rare Diseases. We look forward to future collaborations

    Poništi
  19. 24. ruj 2018.
    Poništi
  20. 20. ruj 2018.

    This week is Mitochondrial Disease Awareness Week The Mito-Find project is empowering Next Generation Sequencing for diagnosing mitochondrial disease, find out more about the project by checking out here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·